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ARTICLE
Syngeneic animal models of tobacco-associated
oral cancer reveal the activity of in situ
anti-CTLA-4
Zhiyong Wang 1,13, Victoria H. Wu1,2,13, Michael M. Allevato1,2,13, Mara Gilardi1,13, Yudou He 3,
Juan Luis Callejas-Valera 4, Lynn Vitale-Cross5, Daniel Martin5, Panomwat Amornphimoltham6,
James Mcdermott1, Bryan S. Yung1,2, Yusuke Goto1, Alfredo A. Molinolo1, Andrew B. Sharabi1,7,
Ezra E.W. Cohen1,8, Qianming Chen9, J. Guy Lyons 10,11,12, Ludmil B. Alexandrov 1,3 & J. Silvio Gutkind 1,2*
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer
worldwide. Tobacco use is the main risk factor for HNSCC, and tobacco-associated HNSCCs
have poor prognosis and response to available treatments. Recently approved anti-PD-1
immune checkpoint inhibitors showed limited activity (≤20%) in HNSCC, highlighting the
need to identify new therapeutic options. For this, mouse models that accurately mimic the
complexity of the HNSCC mutational landscape and tumor immune environment are urgently
needed. Here, we report a mouse HNSCC model system that recapitulates the human
tobacco-related HNSCC mutanome, in which tumors grow when implanted in the tongue of
immunocompetent mice. These HNSCC lesions have similar immune infiltration and
response rates to anti-PD-1 (≤20%) immunotherapy as human HNSCCs. Remarkably, we
find that >70% of HNSCC lesions respond to intratumoral anti-CTLA-4. This syngeneic
HNSCC mouse model provides a platform to accelerate the development of immunother-
apeutic options for HNSCC.
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Tobacco smoking claims the lives of more than 6 millionpeople every year worldwide and is the leading cause ofcancer deaths in the US1,2. Tobacco use has been asso-
ciated with at least 17 types of cancer, primarily in the lung, as
well as with carcinomas arising in the oral cavity, pharynx, and
larynx, often referred to as squamous cell carcinomas of the head
and neck (HNSCC)1,2. HNSCC is a significant public health issue,
with more than 65,400 new cases resulting in 14,600 deaths in
2019 in the US. alone3. The main risk factors include tobacco use
and human papillomavirus (HPV) infection, the latter of which is
predicted to diminish in the future due to successful vaccination
campaigns4,5. Depending on the stage of disease, HNSCC is
typically treated with surgery, radiotherapy, chemotherapy, or a
combination of these interventions. These standard therapies
result in a 5-year survival of ~63%, but patients with more
advanced stages have higher rates of mortality (5 year survival
<50%) and require multimodality treatments, which can lead to
occurrence of significant long-term side effects and lower quality
of life6,7. Despite this more aggressive regimen, up to 30–60% of
HNSCC patients develop tumor recurrence, and often succumb
to the disease8. The recent elucidation of the genomic alterations
underlying HNSCC progression and new immunotherapeutic
strategies may provide an opportunity for the development of
more effective treatment options for HNSCC.
Revolutionary breakthrough discoveries in cancer immunology
have demonstrated that a patient’s own immune cells can be
manipulated to target, attack, and destroy cancer cells9–11. A key
emerging mechanism of tumor immune evasion involves T-cell
exhaustion, whereby T-cell reactivity is impaired due to activation
of T-cell checkpoints, including PD-1 by its ligand, programmed
death ligand 1 (PD-L1) that is expressed by macrophages and
some cancer cells, including HNSCC, restraining T-cell activation
(reviewed in ref. 12). Indeed, immune checkpoint blockade (ICB)
by new immunotherapeutic agents such as pembrolizumab and
nivolumab (anti-PD-1) have recently demonstrated potent anti-
tumor activity in a subset of HNSCC patients13–16. However,
1-year survival and response rates of anti-PD-1 in HNSCC were
only 36 and 14%, respectively, which highlights the urgent need
to identify novel therapeutic options to increase the effectiveness
of ICB for >80% of patients that do not have an objective
response to anti-PD-1/PD-L1 treatment13–15.
Animal models with a full functioning immune system that
also properly resemble human HNSCC etiology and mutational
landscape are desperately needed to accurately recapitulate the
complexity of the tumor immune microenvironment (TIME),
thereby accelerating the search for new immune therapeutic
options. Here, we report a syngeneic murine HNSCC cell panel
that recapitulates typical human tobacco-related HNSCC geno-
mic alterations and mutational landscape, and we show that these
cells form squamous carcinomas (HNSCC) when implanted
orthotopically in the tongue of immune-competent C57Bl/6 mice.
These HNSCC lesions have immune infiltration and response
rates to anti-PD-1 therapies (≤20%) similar to those of human
HNSCCs, thereby providing a platform for the evaluation of new
immune oncology (IO) options for HNSCC treatment.
Results
4MOSC models exhibit tobacco-related genomic landscapes.
Tobacco smoke contains a number of harmful carcinogens that
drive tumorigenesis, the exposure to which strongly correlates
with cancer incidence17.While tobacco-associated cancers are
generally characterized by high mutation frequencies18, we have
recently reported that they can be defined by very specific set of
mutational signatures19. We have also described the optimization
of a carcinogen-induced oral cancer mouse model in which the
compound 4-nitroquinoline-1 oxide (4NQO), a DNA adduct-
forming agent that causes DNA damage and can act as a tobacco-
mimetic promoting Tp53 mutations and oral cancer initiation
and progression20. This model has been used extensively to study
HNSCC progression and preventive and treatment therapeutic
options21–23. However, its direct relevance to the mutagenic
process in human HNSCC has not been previously established.
To begin developing syngeneic HNSCC animal models, we first
isolated four representatives murine HNSCC cell lines from pri-
mary 4NQO-induced tumors in the tongue of C57Bl/6 mice
(designated 4MOSC1-4, short for 4NQO-induced murine oral
squamous cells) (Fig. 1a). The use of SigProfiler24,25 to analyze
exome DNAseq of these HNSCC cells revealed a remarkable
93.9% similarity with human cancer signature 4, which is strictly
associated with tobacco smoking, including in HNSCC, esopha-
geal cancer, and lung cancer19 (Pearson correlation >0.93)
(Fig. 1b and individual 4MOSC cells in Supplementary Fig. 1).
This similarity between 4NQO-induced mutational patterns and
tobacco extended to the presence of a transcriptional strand bias
(Fig. 1c), which reflects the rate of substitution type on each
nucleotide. In contrast, the mutational signature of SCC caused
by DMBA, a carcinogen found in tobacco smoke that is the most
widely used agent for experimental carcinogenesis studies26,
showed only 39.7% similarity with human cancer signature 4.
This suggests that 4NQO-induced SCC lesions better mimic
human tobacco-related human HNSCC. Indeed, these cells also
exhibit typical HNSCC histology and mutations impacting Trp53,
Fat1-4, Keap1, Notch1-3, Kmt2b-d, and others, which represent
some of the most frequently altered gene pathways in HPV−
human HNSCC (Fig. 1d, e, and Supplementary Data 1–4). Of
note, similar to HPV(−) HNSCC samples from The Cancer Gene
Atlas (TCGA), all four 4MOSC cells exhibit typical inactivating
Trp53 mutations in its core DNA binding domain, including hot
spot residues (G245, and R248) that result in loss of tumor-
suppression and gain of tumorigenesis and invasiveness27.
4MOSC lesions mimic the human HNSCC immune micro-
environment. Transplantation of the 4MOSC cells orthotopically
into the tongue of immunocompetent C57Bl/6 mice led to the
formation of well-differentiated HNSCC tumors in two of the cell
lines, 4MOSC1 and 4MOSC2, which exhibit typical HNSCC
histology, as indicated by hematoxylin and eosin (H&E) stained
sections and fluorescence cytokeratin 5 staining (Fig. 2a and
Supplementary Fig. 2a). 4MOSC3 and 4MOSC4 cells also formed
tumors, but they regressed spontaneously after 2 weeks, likely due
to their rejection by the host immune system. Thus, we focused
our studies on 4MOSC1 and 4MOSC2, with emphasis on
investigating whether they have distinct biological properties
reflecting human HNSCC. In this regard, since HNSCC has a
high propensity to metastasize to locoregional lymph nodes
(reviewed in ref. 28), leading to poor prognosis, we next addressed
the metastatic potential of our model. Histological evaluation in
H&E stained sections revealed growth of cancer cells in the lymph
nodes of mice bearing 4MOSC2 but not 4MOSC1 tumors
(Fig. 2b). Interestingly, locoregional lymph node invasion was
observed as early as 2 days postimplantation; and a higher rate of
lymph node metastasis was observed 8 days after 4MOSC2
tumors were established (Supplementary Fig. 2b). 4MOSC2
tumors also exhibited much higher density of lymphatic vessels
staining positive for LYVE-1 than in 4MOSC1 (Fig. 2c), which is
aligned with the strong correlation between intratumoral (IT)
lymphangiogenesis and metastasis in human HNSCC (reviewed
in ref. 29).
By flow cytometry analysis, we found that the immune cells
infiltrating the TIME comprises of cytotoxic T cells (CD8), helper
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T cells (CD4), regulatory T cells (Treg), natural killer cells (NK),
macrophages (M1Φ and M2Φ), as well as polymorphonuclear
myeloid-derived suppressor cells, and monocytic myeloid-derived
suppressor cells30 (Fig. 2d). Notably, although the ratios of
immune infiltration were similar, 4MOSC2 tumors had a
considerably higher level of infiltration than 4MOSC1 (Fig. 2d).
Though cytotoxic CD8 T cells infiltrate both tumors at similar
proportions relative to other immune cells, immunofluorescence
staining showed more abundant distribution within 4MOSC2
tumor cells (Fig. 2e). The more immune inflamed state of
4MOSC2 tumors is likely due to their clearly distinct chemokine
and cytokine profile. Indeed, 4MOSC2 tumors express higher
levels of multiple chemokines (including CXCL1 and CXCL5)
and growth factors (such as G-CSF, GM-CSF) than in 4MOSC1
tumors, which may contribute to the recruitment and survival of
MDSCs and inflammatory cells, as well as VEGF that may explain
the higher density of lymphatic vessels (Supplementary Fig. 3).
To determine whether this immune infiltration is associated
with antigen-driven immunogenicity, we next investigated
whether the 4MOSC tumors could generate memory immune
responses. Initial exposure of mice to tumor cell antigens was
achieved by first irradiating tumor cells and then injecting into
the tongue of C57Bl/6 mice with or without polyinosinic-
polycytidylic acid (poly IC) as an immune adjuvant. Irradiated
4MOSC1 and 4MOSC2 cells did not form tumors, and mice
vaccinated with irradiated tumor cells alone or irradiated tumor
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cells with poly IC failed to form tumors when they were
subsequently rechallenged with nonirradiated cancer cells, while
naïve mice and mice with poly IC alone still formed tumors. This
suggests that the mice were able to develop an immunological
memory to 4MOSC antigens even in the absence of an immune
adjuvant. This may be due to the fact that irradiation can induce
inflammatory cell death31, which contributes to immunogenicity.
Taken together, our results suggest that these syngeneic HNSCC
cell lines are highly immunogenic (Supplementary Fig. 4).
These findings indicate that these mice are capable of
generating adaptive immune responses against 4MOSC tumor
antigens. However, 4MOSC tumors still grow and lead mice to
succumb to disease, implying that these tumors can evade
immunity by inducing an immune suppressive microenviron-
ment. The expression of PD-L1, the ligand for the T-cell
inhibitory receptor PD-1, is often high in HNSCC patients
(46–100% of tumors)32 and has been shown to suppress cytotoxic
T cells that destroy tumors and also serves as a biomarker
(reviewed in ref. 33) predicting a better response to anti-PD-1
therapy. We found that PD-L1 is constitutively expressed on both
tumor (CD45−) and immune cells (CD45+), but the frequency of
4MOSC1 tumor cells that expressed PD-L1 was much higher
than the frequency of 4MOSC2 cells expressing PD-L1 (Fig. 2f).
Though most tumor-infiltrating immune cells expressed PD-L1,
MDSCs, tumor-associated macrophages and MHCII+ antigen-
presenting cells infiltrating the tumor comprise of the majority of
PD-L1hiCD45+ immune cells (Supplementary Fig. 5). Activated
(CD44+) CD8 T cells infiltrating both 4MOSC1 and 4MOSC2
tumors exhibited characteristic immune checkpoint molecules,
PD-1, cytotoxic T lymphocyte associated protein 4 (CTLA-4),
T-cell immunoglobulin mucin 3 (TIM-3), and lymphocyte
activation gene 3 (LAG-3) (Fig. 2g). Interestingly, there were
higher immune checkpoint molecules in tumor-infiltrating
lymphocytes (TILs, green) than in lymph nodes (blue) or blood
(red) in both tumors (Fig. 2g). Similar expression patterns were
seen for tumor-infiltrating CD4 T cells, but there was a higher
frequency of Tregs expressing CTLA-4 compared with non-Treg
CD4 T cells (Supplementary Fig. 6).
Limited response of syngeneic HNSCC tumors to PD-1
blockade. To interrogate whether blocking the interaction of
PD-1 and PD-L1 could cause tumor regression, we first studied
4MOSC1 tumors, the syngeneic HNSCC cell line that has higher
PD-L1 expression. Most mice showed an initial decreased tumor
volume after anti-PD-1 treatment (Fig. 3a), with a consequent
increased overall survival (Fig. 3b) (p < 0.001). Interestingly,
however, 80% of mice that initially responded to anti-PD-1
(partial response) showed tumor relapse and eventually
succumbed to disease burden, while 10–20% of the mice showed
complete responses (CR) (Fig. 3a, b, and Supplementary Fig. 7a).
Due to the limited tumor size and number of infiltrating cells, we
could not perform a comprehensive analysis of immune cell
infiltration in individual tumors at the beginning of the treatment.
However, 4MOSC1 tumors from mice treated with anti-PD-1
showed clearly significant higher CD8 infiltration (p < 0.01)
compared with tumors from untreated mice by FACS analysis of
TILs and by immune fluorescence analysis of treated tissues
(Fig. 3c, d, respectively). All responses to anti-PD-1 were abol-
ished if CD8 T cells were eliminated from mice (Fig. 3e and
Supplementary Fig. 7b). Together, these data indicate a CD8-
dependent anti-PD-1 response in mice with 4MOSC1 tumors, but
with limited durable disease control or tumor regression, which is
similar to the clinical response to anti-PD-1 therapies in HNSCC
patients14,16. To our surprise, although metastasis was not
observed in 4MOSC1 control mice (see above), the cervical lymph
nodes of CD8-depleted mice with 4MOSC1 tumors showed
tumor invasion, as indicated by cytokeratin 5 staining (Fig. 3f)
and visualization with H&E staining (Supplementary Fig. 7c)
suggesting that immune surveillance may prevent the metastatic
spread of this tumor. In contrast, mice bearing 4MOSC2 tumors
failed to respond to anti-PD-1 treatment (Fig. 3g and Supple-
mentary Fig. 7d), suggesting 4MOSC2 serves as a less differ-
entiated, high immune cell-infiltrated, metastatic, and PD-L1-low,
and anti-PD-1 resistant model (Fig. 3g, and Supplementary
Fig. 7d).
The PD-1 blocking antibodies used are mouse specific, hence
treatment failure is not expected to be due to neutralizing
antibodies against human IgG. We next isolated 4MOSC1 cells
from mice showing limited response to anti-PD-1 as an approach
to achieve a more clear perspective of immune suppressive
mechanisms that may account for the recurrence and progression
of 4MOSC1 tumors in mice treated with anti-PD-1. We then
engrafted sensitive (parental) and anti-PD-1 (αPD-1) resistant
4MOSC1 cells and treated mice with or without anti-PD-1.
Among all immune cells examined, αPD-1 resistant tumors
recruited significantly more Ly6-Ghi PMN-MDSCs than the
parental cell line, and treatment with anti-PD-1 in these αPD-1
resistant tumors significantly increased immunosuppressive
PMN-MDSCs, suggesting that MDSCs may be deterring cytotoxic
immune responses. Moreover, upon anti-PD-1 treatment, there
were significant increases in LAG-3 and TIM-3, and greater
increase in CTLA-4 in CD8 T cells isolated from the αPD-1
resistant tumors when compared with their parental tumors,
while increases in LAG-3 in CD4 T cells were comparable
between parental and αPD-1 resistant tumors (Supplementary
Fig. 8). Altogether, these data suggest that recurrence and
Fig. 1 Development of a novel syngeneic mouse model for oral squamous cell carcinoma. a Experimental scheme of 4NQO syngeneic model. C57Bl/6
mice were given 4NQO (50 μg/mL) in the drinking water for 16 weeks and then regular water until week 22. Cells were isolated from the lesions, cultured,
and then implanted into the tongue of wild-type C57Bl/6 mice. The Scheme was drawn by Yagi and Allevato. b Mutational signatures associated with
tobacco smoking. The somatic mutational profiles of the four lesions from mice exposed to 4NQO were correlated to known mutational signatures in
human cancer (Pearson correlation > 0.93)19,24. Top, Signature 4 extracted from cancers associated with tobacco smoking, this signature was found only
in cancer types in which tobacco smoking increases risk and mainly in those derived from epithelia directly exposed to tobacco smoke19; middle, the
pattern of a mutational signature of lesions from mice exposed to 4NQO, compilation of all four samples analyzed; bottom, the pattern of a mutational
signature of lesions from mice exposed to DMBA. The similarity between signature tobacco smoking associated HNSCC and signature 4NQO is 93.9%;
and the similarity between signature tobacco smoking associated HNSCC and signature DMBA is only 39.7%. c Percentage of somatic substitutions
located in translated or untranslated in tobacco smoking associated HNSCC patients (left), 4NQO derived lesions (middle) and DMBA derived lesions
(right). d Graphical matrix representation of the individual mutations in four syngeneic cell lines (4MOSCs) isolated from lesions from mice exposed to
4NQO. Listed are the alterations most frequently observed in human HNSCC and the corresponding percentage of mutations. Mutations (red), or no
mutations (blue) are listed in rows and four different cell lines are in column. eMutational plot of TP53mutations in 243 HPV-negative tumor samples from
TCGA (top) and of four syngeneic cell lines (4MOSCs) (bottom). Frequency of mutation is depicted by height of lollipop, blue circles represent mutations
unique to human or mouse, and red circles depict mutations in common between human and mouse HNSCCs.
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Fig. 2 Characterization of 4NQO-induced murine oral squamous cell model. a Left panel, C57Bl/6 mice were implanted with 1 × 106 of either 4MOSC1 or
4MOSC2 cells into the tongue. Tongue lesions when the tumor volume reached ~100mm3. Middle panel, representative H&E staining of histological tissue
sections from mouse tongues with 4MOSC1 or 4MOSC2 tumors. Right, representative pictures of tumors stained to show expression of cytokeratin 5
(CK5, green) and DAPI (blue) (n= 3 mice per group). b Top panel, representative H&E stain of a nonmetastatic cervical lymph node from mice with
4MOSC1 tumors. Bottom panel, representative H&E stain of a metastatic cervical lymph node from mice with 4MOSC2 tumors. Metastatic growth of
4MOSC2 cells into the lymph node is depicted with a dotted line in the bottom area (n= 5 mice per group). c Representative tumor tissue sections stained
for LYVE-1 by immunohistochemistry in 4MOSC1 or 4MOSC2 tumors (n= 3 mice per group). d Absolute number of immune cells infiltrating 4MOSC1 or
4MOSC2 tumors. Shown is the average number of live cells infiltrating per mm3 of tumor (n= 3 mice per group). e Immunofluorescent staining of CK5 and
CD8 to show squamous cell character of the lesion and CD8 infiltration in mice with 4MOSC1 or 4MOSC2 tumors, respectively (n= 3 mice per group)
(CK5, green; CD8, red; DAPI, blue). 4MOSC1 or 4MOSC2 tumors were isolated from mice and mechanically and enzymatically digested. Single-cell
suspension was then stained with CD45, Nk1.1, CD3, CD8, CD44, PD-L1, PD-1, CTLA-4, LAG-3, and TIM-3 fluorescent labeled antibodies and analyzed by
flow cytometry. Shown are representative flow cytometry plots of f the frequency of tumor cells (CD45 negative) expressing PD-L1 and g the frequency of
CD8+/CD44+ cells expressing inhibitory receptors PD-1, CTLA-4, LAG-3, and TIM-3 in individual tumors (n= 4 mice per group). Contour plots of
lymphocytes from tumor (green), and corresponding cervical lymph nodes (blue), and blood (red) are overlaid and the frequencies of tumor CD8+/CD44
+ T cells expressing each inhibitory receptor are shown (n= 4 mice per group).
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acquired resistance to anti-PD-1 in 4MOSC1 tumors may be
conferred by increased MDSC recruitment and higher expression
of additional CD8 T-cell inhibitory receptors.
Immune modulation by intratumoral (in situ) delivery of ICB.
A defining feature of most HNSCCs is the superficial and
mucosal localization of the disease. Unlike many other cancer
types, most HNSCC patients have tumors that can be readily
visualized and accessed by surgeons, providing an opportunity to
use IT drug delivery. To investigate whether IT injection of anti-
PD-1 has improves activity in our model, we compared the
effectiveness of using a lower dose anti-PD-1 treatment with
standard systemic delivery. We found that mice treated with just
half the dose of anti-PD-1 locally showed similar antitumor
responses compared with mice with full dose systemic treatment
(Fig. 4a). Furthermore, immunofluorescence analysis revealed
that IT delivery led to significantly higher PD-1 antibody dis-
tribution in tumors and cervical lymph nodes and lower
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After tumors reached ~30mm3, mice were treated IP with 10 mg/kg of isotype control or anti-PD-1 (n= 10 per group). Individual growth curves of
4MOSC1 tumor-bearing mice are shown. b A Kaplan–Meier curve showing the survival of mice from a. The death of animals occurred either naturally,
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c Absolute number of live CD45+CD3+CD8+ T cells infiltrating 4MOSC1 tumors with or without anti-PD-1 treatment. Shown is the average of the
number of live CD8 T cells infiltrating per mm3 of tumor (n= 4 mice per group; two-sided Student’s t test; data are represented as mean ± SEM).
d Immunofluorescent staining of CD8 highlights an increase in CD8 T-cell recruitment with anti-PD-1 treatment. Shown is the average CD8 positivity
was by three regions of interest (ROI) per mouse (n= 3 mice per group; two-sided Student’s t test; data are represented as mean ± SEM). e Dependency
of anti-PD-1 on CD8 T cells. C57Bl/6 mice were treated with CD8 T cell depleting antibody daily for 3 days before tumor implantation and then once a
week after. Mice were then implanted with 1 × 106 of 4MOSC1 cells into the tongue. After tumors reached ~30 mm3, mice were treated IP with 10 mg/kg
isotype control or 10 mg/kg anti-PD-1 (n= 5 per group). Individual growth curves of 4MOSC1 tumor-bearing mice are shown. f Immunofluorescence
staining of CK5 and Ki-67 in cervical lymph nodes of control or CD8-depleted 4MOSC1-bearing mice. Metastatic lesions in the lymph nodes showed
abundant Ki-67+ proliferating tumor cells (n= 5 mice per group). g C57Bl/6 mice were implanted with 1 × 106 of 4MOSC2 cells into the tongue. After
tumors reached ~30mm3, mice were treated IP with 10 mg/kg isotype control or 10 mg/kg anti-PD-1 (n= 5 per group). Individual growth curves of
4MOSC2 tumor-bearing mice are shown.
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distribution in the spleen as a peripheral organ when compared
with systemic delivery (Fig. 4b).
To investigate if there are local, differential immune signature
alterations associated with IT drug delivery, we performed a
comprehensive immune profiling using the nCounter PanCancer
Mouse Immune Profiling gene expression platform (NanoString
Technologies). Using 770 immune-related genes, we profiled
immune cells infiltrating the tumor following treatment with
systemic or IT anti-PD-1, and compared it with another FDA-
approved immunotherapy, CTLA-4 blockade. Relative to the
tongues from healthy mice, mice bearing 4MOSC1 tumors have
elevated expression of a majority of immune cell-associated genes.
While systemic anti-PD-1 treatment increased the T-cell
signature, IT delivery enhanced it further while also increasing
gene expression of NK and genes related to cytotoxic immune
cells (Fig. 4c). Interestingly, albeit used initially as a control, this
analysis revealed that IT treatment with anti-CTLA-4 led to even
more robust T cell, cytotoxic cell, and macrophage responses, and
an increased CD8 T-cell tumor infiltration (Fig. 4c, d). In
addition, while anti-PD-1 increased Treg associated gene
signatures, anti-CTLA-4 appears to diminish it, which was
confirmed by flow cytometry analysis of treated tumors (Fig. 4c,
e). In order to further explore the role of Tregs in 4MOSC1
tumors, we utilized the FoxP3DTR transgenic mice that have been
widely used to study the immunosuppressive role of Tregs in
cancer34. Treg depletion with diphtheria toxin (DT) led to
significant reduction of tumor growth, and combination of Treg
depletion with anti-PD-1 led to complete responses in most mice
(Supplementary Fig. 9). This strongly suggests that Tregs may
prevent the full therapeutic activity of anti-PD-1, and that the
reduction of the immunosuppressive activity of Tregs may
represent a mechanism explaining the higher therapeutic
responses to anti-CTLA-4 treatment (Supplementary Fig. 9).
The majority of 4MOSC1 lesions respond to anti-CTLA-4.
Given that immune stimulatory effects were enhanced following
anti-CTLA-4 treatment compared with anti-PD-1 treatment, we
sought to determine whether mice with 4MOSC1 tumors can also
respond to CTLA-4 blockade. CTLA-4 blockade systemically and
IT elicited a robust antitumor effect, with 90% of the mice
exhibiting a CR (Fig. 5a and Supplementary Fig. 10a) and effi-
ciently resisted engraftment when rechallenged with fresh
4MOSC1 cells. Similar to anti-PD-1 treatment, IT delivery
resulted in significantly higher anti-CTLA-4 antibody distribution
in tumors and cervical lymph nodes and lower distribution in the
spleen (Fig. 5b). Antitumor immunity of anti-CTLA-4 is also
CD8 dependent, as CTLA-4 inhibition resulted in significantly
increased infiltration of and IFNγ production by CD8+ T cells
(Fig. 5c, Supplementary Fig. 11), and its antitumor activity was
abolished by the depletion of CD8 T cells (Supplementary
Fig. 10b). Adding to this, when tumor-infiltrating CD8 T cells
were isolated and cultured with tumor cells in vitro, they were
able to kill the tumor cells, and CD8 T cells from anti-PD-1- and
anti-CTLA-4-treated mice were able induce significantly more
cancer cell death (Fig. 5d, e). Of interest, 4MOSC2 tumors also
failed to respond to anti-CTLA-4 treatment (Supplementary
Fig. 10c), providing a model that is resistant to both forms of
immunotherapy for future exploration of immunotherapy resis-
tance and the use of strategic combinatorial modalities.
Discussion
HNSCC is an immunosuppressive disease, in which the tumor
deploys multiple mechanisms to evade immune surveillance
and antitumor immune responses through the accumulation of
immunosuppressive cytokines, impairment of cytotoxic activity
and antigen-presenting function, and induction of T-cell exhaus-
tion (reviewed in ref. 12). Based on this knowledge, numerous
immunotherapeutic strategies were developed, including ICB,
cancer vaccines, therapeutic cytokines, adoptive T-cell transfer,
and adjuvants that may trigger innate immune responses such as
TLR and STING agonists (reviewed in ref. 12). Clearly, suitable
experimental systems that can model clinical responses are
urgently needed to study and improve the effectiveness of IO
approaches in HNSCC. Here, we developed a panel of C57Bl/6-
derived syngeneic cells that resemble human HNSCCs closely with
unique features: (i) The HNSCC cells have nearly identical
tobacco-associated mutational signatures and genomic aberra-
tions; (ii) they can be orthotopically transplanted into the tongue
of immunocompetent C57Bl/6 mice; (iii) the tumors are histolo-
gically HNSCCs with abundant lymphangiogenesis and potential
for lymph node metastasis; and (iv) the tumors exhibit abundant
immune infiltration and are immunogenic, the latter as judged by
their ability to induce immunological memory when used to
vaccinate mice. These animal models may provide an opportunity
to investigate the mechanisms driving intrinsic and acquired
resistance to IO agents, as well as to identify novel therapeutic
options increasing the response of currently available immu-
notherapies in HNSCC patients.
Tobacco use is one of the major risk factors for initiation and
progression of HNSCC, and serves as an important prognostic
factor for survival and mortality after cancer diagnosis (reviewed
in ref. 35). In a recent study, we analyzed somatic mutations and
DNA methylation in 5243 samples comprising of cancers for
which tobacco smoking confers an elevated risk, which helped
define the human tobacco-associated cancer signature19.
Remarkably, although tobacco smoke is made up of thousands of
chemicals, including more than 60 carcinogens17, we found that
4NQO exposure was sufficient to mimic the tobacco carcinogenic
signature. This is supported by compelling evidence demon-
strating that 4NQO-induced SCC lesions exhibit near identical
association (~94%) with the tobacco mutational landscapes,
recapitulating human HNSCC. This is in contrast with the
mutational signature caused by DMBA (<40% similarity), which
although representing a widely used tobacco carcinogen26, may
not be as effective as 4NQO in reflecting the human tobacco-
associated genetic signatures19.
In this regard, currently available syngeneic HNSCC models
include SCCVII cells, HPV+ SCC cells designated MEER36 and a
panel of mouse HNSCC cell lines from DMBA-treated mice
(MOC1 and MOC2)37. Though widely used, SCCVII cells are in
fact derived from a spontaneously formed skin SCC lesion in
C3H mice38. MEER and MOC1/MOC2 models develop tumors
in immune-competent C57Bl/6 mice when implanted in the
flanks, which may not reflect the HNSCC TIME, albeit MOC1/
MOC2 can also grow tumors orthotopically even if their immune
status has not been characterized in this anatomical location39.
These tumors are driven by Ras oncogenes (Kras in MEER and
MOC2, and Hras in MOC1)36,37,40, which are very potent
oncogenic drivers, but infrequently (<6%) mutated in human
HNSCC41, albeit higher frequencies have been reported in some
demographic groups42. Thus, although quite useful for cancer
immunology studies, these cellular systems may not mimic fully
the tobacco-induced carcinogenic process driving most human
HNSCCs. Despite the fact that these cell lines have dramatically
different genomic alteration profiles, some of these cells respond
to ICB similarly to 4MOSC1 cells, suggesting that the determi-
nants of immune responses may be independent of the under-
lying driving mutations that lead to HNSCC formation.
Nonetheless, neither Hras, Kras, nor Nras genes are mutated in
the 4MOSC panel, suggesting that these cells may harbor pathway
specific alterations likely more relevant to human malignancy.
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Fig. 5 Mice with 4MOSC1 tumors show nearly complete response to anti-CTLA-4. a C57Bl/6 mice were implanted with 1 × 106 of 4MOSC1 cells into the
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and spleen of treated mice. DAPI staining for nuclei is shown in blue (n= 4 mice per group). c Immunofluorescent staining of CD8 highlights an increase in
CD8 T-cell recruitment with anti-CTLA-4 treatment. Quantification of CD8 T cells with or without anti-CTLA-4 treatment was done by immunofluorescent
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(10%) was used to treat 4MOSC1 as a positive control, and DRAQ7 was added in the culture medium to mark dead cells (red). d Real time live-imaging
experiments were performed using the 880 confocal fast scan (Zeiss), and representative images of tumor cell killing (CD8 T cells from anti-CTLA-4
group) are shown at the indicated times. e Quantification of dead cancer cells at the end of experiment. (n= 3 mice per group; two-sided Student’s t test;
data are represented as mean ± SEM).
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Taken together, the unique features of our syngeneic HNSCC
animal model provide a resource to investigate novel IO pre-
clinical approaches for HNSCC treatment.
Seminal studies have shed light on T-cell exhaustion in human
cancers, where CD8 T cells lose proliferative capacity, the ability
to produce tumor necrosis factor (TNFα), interleukin-2, and
interferon-γ (IFNγ), and upregulation of inhibitory checkpoint
receptors, such as PD-1 and CTLA-49–11. Recently, the successes
of ICB to reverse T-cell exhaustion in multiple cancers illustrates
the potential of therapeutic strategies targeting these negative
regulatory pathways43. In the clinic, PD-1 blockade offers 10–20%
clinical improvement in HNSCC13–15, which was modeled simi-
larly in our study where anti-PD-1 led to regression of 4MOSC1
tumors in only ≤20% of mice. The increase in CD8 T cells seemed
to provide only temporary cytotoxic activity in mice treated with
anti-PD-1, as we observed the reoccurrence of tumors in the
majority of treated mice. Surprisingly, we saw enhanced anti-
tumor responses with anti-CTLA-4 treatment, where most
4MOSC1 tumor-bearing mice showed complete responses and no
tumor reoccurrence. The resulting increase in CD8 T cells fol-
lowing anti-CTLA-4 treatment confirmed that targeting check-
points may revitalize immunological effect of exhausted T cells, at
least at the cellular level. One explanation for these strikingly
different responses could be that PD-1 blockade may induce
compensatory upregulation of FoxP3+ Treg cells44,45, as it
occurred in our anti-PD-1-treated mice but not in anti-CTLA-4-
treated mice. In fact, CTLA-4 inhibition led to significantly lower
levels of FoxP3+ Treg cells in the tumors. In this regard, while
both blocking antibodies can lead to cytotoxic CD8 T-cell
responses, anti-CTLA-4 may provide additional antitumor
immunity by depleting Tregs that mediate an immune-
suppressive environment (reviewed in ref. 46). Moreover, PD-1
blockade predominantly activates T cells within the tumor,
whereas anti-CTLA-4 may activate T cells primarily in the lymph
nodes46, in which high levels of anti-CTLA-4 can be achieved by
IT delivery. These and yet to be identified mechanisms may
underlie the increased response to anti-CTLA-4 in some anti-PD-
1 refractory HNSCC lesions, whose elucidation may provide
biomarkers for the selection of patients that may benefit from
anti-CTLA-4 treatment after failing to anti-PD-1 therapy.
In this regard, the recent CONDOR trial demonstrated no
benefit to adding tremelimumab, a humanized monoclonal
antibody against CTLA-4, to durvalumab, which blocks PD-L1, in
patients with relapsed HNSCC47. However these are unique
biological agents, as tremelimumab may display lower clinical
activity than the most frequently used anti-CTLA-4 antibody,
ipilimumab48. In addition, the use of ICB in earlier stages of
disease may have improved activity compared with relapsed/
metastatic setting as there is potentially less immune editing and
immune evasion in earlier stages of disease. In addition, one
limitation of using anti-CTLA-4 for a variety of cancers in the
clinic is its toxicity49. Systemic delivery of IO agents have been
shown to be responsible for severe immune-related adverse events
(irAEs), such as colitis, dermatitis, uveitis, and hypophysitis49.
These adverse events are very toxic, at times irreversible and can
even be life-threatening. With this in mind, IT injection may
enhance tumor-specific T-cell responses while reducing sig-
nificant systemic exposure to healthy tissue and off-target
toxicities50,51. In addition, IT immunotherapy usually causes
in situ priming of antitumor immunity, which may allow a
patient’s own tumor cells to be used as a therapeutic vaccine50,51.
In our study, a lower dose of IT anti-PD-1 showed similar
therapeutic effects as systemic delivery of a higher dose, and IT
anti-CTLA-4 led to complete regression of most 4MOSC1 tumors
that are primarily refractory to anti-PD-1. In addition, IT
injection led to higher distribution of the antibody in the tumor
and cervical lymph nodes, but less in the spleen as a surrogate for
distribution in peripheral organs. This suggests that the IT route,
which is feasible in HNSCC, may serve as a more effective and
less toxic therapeutic strategy for this tumor type, a possibility
that may have readily applicable clinical implications, and hence
warrant further investigation.
Certainly, some HNSCC tumors have minimal immune infil-
tration, and may require a multipronged approach to facilitate
immune recruitment and activation of the antitumor immune
response52,53. Other HNSCC lesions are completely refractory to
ICB, even if highly immune infiltrated. In this regard, mice
implanted with 4MOSC2 failed to respond to anti-PD-1 and anti-
CTLA-4 therapy, likely due to the presence of abundant immune
suppressive MDSC30 in the TIME, which may restrict DC and/or
CD8+ T-cell function in addition to promoting T-cell exhaustion.
Therefore, this 4MOSC model system is ideal for investigating
mechanisms of immunotherapy resistance, as well as testing novel
multimodal immunotherapies and/or optimization of potential
combinations of ICB with chemo- and radiotherapies. Altogether,
our findings suggest that our novel syngeneic HNSCC animal
models, which strongly mimic tobacco-associated HNSCC and
typical clinical situations, may provide experimental tools to
investigate interplays between HNSCC and the immune system as
well as provide unique opportunities to identify more effective
therapeutic strategies for tobacco-associated HNSCC, which are
associated with poor prognosis and reduced response to most
currently available treatment options.
Methods
Reagents. 4NQO was purchased from Sigma-Aldrich, dissolved in propylene
glycol (Sigma-Aldrich) as a stock solution (4 mg/mL) and stored at 4 °C. PD-1
antibody (clone J43, catalog #BE0033-2), CTLA-4 antibody (clone 9H10, catalog
#BP0131), isotype antibody (catalog # BE0091), and CD8 depletion antibody
(Clone YTS 169.4, catalog #BE0117) were obtained from Bio X Cell (West Leba-
non, NH, USA). Fluorochrome-conjugated antibodies were purchased from Bio-
Legend and BD Biosciences.
Establishment of cell lines and tissue culture. Female C57Bl/6 mice (4–6 weeks
of age and weighing 16–18 g) were purchased from Charles River Laboratories
(Worcester, MA, USA). 4NQO was diluted in the drinking water to a final con-
centration of 50 μg/mL to animals and was changed weekly. After 16 weeks, all
animal cages were reverted to regular water until week 22. Animals were eutha-
nized on week 22 for tissue retrieval. Single lesions were dissected, digested, and
cells were isolated to establish 4MOSC cell lines.
DNA sequencing, genomic, and tobacco signature analysis. Raw sequencing
data were aligned to the mm10 reference genome using BWA54. Somatic mutations
were identified by comparing the sequencing data from each cancer sample to the
sequencing data from a normal tissue derived from the tail of one of the mice (all
mice were genetically identical). To ensure robustness of the results, a consensus
variant calling strategy was leveraged in which somatic mutations were identified
using three independent bioinformatics tools: Strelka255, Varscan256, and GATK4
Mutect257. Any mutation found in two out of the three variant callers was con-
sidered a bona fide somatic mutation. Additional filtering to remove any residual
germline contamination was applied and any mutation found in Mouse Genome
Project or shared among all four cancers was discarded. Somatic mutational pro-
files were derived using the immediate sequencing context by evaluating the base 5′
and the base 3′ to each single point mutation. In addition, transcriptional strand
bias was evaluated by considering all protein coding genes. Mutational signatures
were extracted using our previously developed computational framework
SigProfiler24,25. SigProfiler can be downloaded freely from: https://www.
mathworks.com/matlabcentral/fileexchange/38724-sigprofiler.
Gene mutation analyses were performed comparing our four syngeneic cells to
a HNSCC provisional dataset containing 243 HPV− tumor samples from the
publicly available consortium, TCGA40. Mutational plots of p53 mutations
observed in characterized HNSCC samples from TCGA and four of our syngeneic
cell lines were summarized using the “lolipop” mutation diagram generator58.
In vivo mouse experiments and analysis. All the animal studies using HNSCC
tumor xenografts and oral carcinogenesis studies were approved by the
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Institutional Animal Care and Use Committee (IACUC) of University of Cali-
fornia, San Diego, with protocol ASP #S15195. Mice at Moores Cancer Center,
UCSD are housed in micro-isolator and individually ventilated cages supplied with
acidified water and fed 5053 Irradiated Picolab Rodent Diet 20 from lab diet.
Temperature for laboratory mice in our facilitiy is mandated to be between 65–75 °
F (~18–23 °C) with 40–60% humidity. All animal manipulation activities are
conducted in laminar flow hoods. All personnel are required to wear scrubs and/or
lab coat, mask, hair net, dedicated shoes, and disposable gloves upon entering the
animal rooms. 4MOSC1 and 4MOSC2 cells were transplanted (1 million per
mouse) into the tongue of female C57Bl/6 mice (4–6 weeks of age and weighing
16–18 g). When tumors were formed (on day 5–6), the mice were first randomized
into groups. For drug treatment, the mice were treated by either intraperitoneal
(IP) or IT injection with isotype control antibody, PD-1 antibody, or CTLA-4
antibody (IP 10 mg/kg, IT 5 mg/kg, three times a week) for 3 weeks. The mice were
then euthanized after the completion of the treatment (or when control-treated
mice succumbed to tumor burdens, as determined by the ASP guidelines) and
tumors were dissected for flow cytometric analysis or histologic and immunohis-
tochemical evaluation.
For Foxp3DTR mice, we use Foxp3-GFP-DTR mice (C57BL/6-Tg(Foxp3-DTR/
EGFP); from JAX in C57BL/6 background) (6–8 weeks of age and weighing 18–22
g). To deplete Tregs, mice were injected IP with 500 ng of diphtheria toxin (DT;
Sigma-Aldrich), diluted in PBS.
Chemokine expression profile. Tongue tumors were dissected and lysed in RIPA
lysis buffer supplemented with protease and phosphatase inhibitors59. Samples
were run on the Mouse Chemokine Array 44-Plex (EVE Technologies, Canada).
Immunofluorescence and image quantification. Briefly, tissues (tongue, cervical
lymph nodes, and spleen) were harvested, fixed, and paraffin embedded. Slides
were stained for CK5 (Fitzgerald, 20R-CP003) (1:500) and CD8 (abcam, ab22378)
(1:400) antibodies. Quantification of immune infiltration was done using QuPath,
an open source software for digital pathology image analysis60. For the quantifi-
cation, at least three regions of interest (ROI) were selected for each condition and
the percentage of positive cells for the CD8 marker was calculated. In order to
quantify the immune-fluorescent-stained Foxp3 and CD8 positive cells in the
Foxp3DTR mice, we quantified the number of positive cells in each ROI. CD8
antibody (catalog # ab22378) (1:400) was purchased from Abcam (Cambridge,
United Kingdom) and FoxP3 antibody (catalog #D608R) (1:200) was purchased
from Cell Signaling Technology (Danvers, MA).
TIL isolation and flow cytometry. Tumors were dissected, minced, and resus-
pended in complete media (DMEM with 10% FBS and 1% antibiotics) supple-
mented with Collagenase-D (1 mg/mL; Roche) and incubated at 37 °C for 30 min
with shaking to form a single-cell suspension. Tissue suspensions were washed with
fresh media and passed through a 100-µm strainer. Samples were washed with PBS
and immediately processed for live/dead cell discrimination using BD HorizonTM
Fixable Viability Stain 510. Cell surface staining was done for 30 min at 4 °C with
the following antibodies (all from BioLegend, San Diego, CA): CD45 (30-F11)
(1:100), CD3 (145-2C11) (1:400), CD8a (53-6.7) (1:100), CD4 (RM4-4) (1:400),
NK1.1 (PK136) (1:400), CD24 (M1/69) (1:100), MHCII (M5/114.15.2) (1:800),
Ly6-G (1A8) (1:400), Ly6-C (HK1.4) (1:100), F4/80 (T45-2342) (1:100), CD103
(2E7) (1:100), CD11b (M1/70) (1:200), CD11c (HL3) (1:100), PD-1 (29 F.1A12)
(1:100), TIM-3 (B8.2C12) (1:100), and CD44 (IM7) (1:100). Intracellular staining
for inhibitory receptors LAG-3 and CTLA-4 was done using the BD Cytofix/
Cytoperm kit and stained with the LAG-3 (C9B7W) (1:100) and CTLA-4 (UC10-
4B9) (1:100) antibodies. Intracellular staining for FOXP3 was performed using the
eBioscience FOXP3/Transcription factor buffer set from invitrogen and stained
with the FOXP3 (MF23) antibody. All flow cytometry data acquisition was done
using BD LSRFortessa and analyzed using FlowJo software. TIL count was deter-
mined using BD TrucountTM tubes. Immune cells were identified by the following
characteristics: cytotoxic T cells (CD45+Thy1.2+CD8+), helper T cells (CD45+
Thy1.2+CD4+), Treg (CD45+Thy1.2+CD4+FoxP3+), NK cells (CD45+Thy1.2−
NK1.1+), macrophages (CD45+Thy1.2−NK1.1−CD11b+CD11c−LY6ClowLY6Glow
CD24+F4/80+), PMN-MDSCs (CD45+Thy1.2−NK1.1−CD11b+CD11c−LY6Clow
LY6G+), and M-MDSCs (CD45+Thy1.2−NK1.1−CD11b+CD11c−LY6C+
LY6Glow). A representative flow cytometry gating strategy is depicted in Supple-
mentary Fig. 12.
Antigen specific T-cell cytotoxicity assay. 4MOSC1 tumors were mechanically
and enzymatically digested as described above and tumor-derived T cells were
isolated by the Murine CD8a+ T Cell Isolation Kit from Miltenyi Biotec (Bergisch
Gladbach, Germany). 4MOSC1 cells were plated in keratinocyte media in the 24-
well µ-plate from ibidi (Grafelfing, Germany) and when cells grew to 60% con-
fluency, T cells were added at a 1:10 cancer cell to T cells ratio. The viability dye,
DRAQ7, was added in the culture medium to discriminate cancer cell killing by
T cells, and T cells were labeled with Vybrant Dil Cell-Labeling Solution from
Invitrogen (Carlsbad, CA). Overnight live-imaging was captured in real time by the
Zeiss LSM 880 confocal with Airyscan FAST.
NanoString analyses. RNA was isolated from tumor samples using the RNeasy
Micro Kit (Qiagen 74004). Hybridization of samples was done according to the
NanoString Hybridization Protocol for nCounter XT CodeSet Gene Expression
Assays. Samples were run on the nCounter SPRINT Profiler with the nCounter
PanCancer Mouse Immune Profiling gene expression platform. Analysis of gene
expression was done using the Advanced Analysis module on the nSolver software.
Statistics and reproducibility: Statistical data analyses, variation estimation, and
validation of test assumptions were carried out with GraphPad Prism version
7 statistical analysis program (GraphPad Software, San Diego, CA). All analyses
were performed in triplicate or greater and the means obtained were used for
independent t-tests, ANOVA, or longitudinal data analysis method. The asterisks
denote statistical significance (nonsignificant or ns, P > 0.05; *P < 0.05; **P < 0.01;
and ***P < 0.001). All the data are reported as mean ± standard error of the mean
(S.E.M.). For all experiments, each experiment was repeated independently with
similar results for at least three times.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The whole exome sequencing data of murine 4NQO-induced syngeneic cell lines have
been deposited in the NCBI Sequence Read Archive (SRA) database under the accession
code PRJNA575532. The whole exome sequencing data referenced during the study are
available in a public repository from the NCBI SRA website. The source data underlying
Fig. 1b–e and Supplementary Fig. 1 are provided as Supplementary Data 1–4 in microsoft
excel format. All the other data supporting the findings of this study are available within
the article and its Supplementary Information files and from the corresponding author
upon reasonable request. A reporting summary for this article is available as a
Supplementary Information file.
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